SCHEMBL23577302

SCHEMBL23577302

CN(c1ccccc1)c1nc2nncn2c2cc(-c3ccncc3)ccc12

nearest known ligand 0.39

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.39
PDE5A O76074 2/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
ADORA2A P29274 1/20 0.34
IMPDH2 P12268 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23577125 0.93 PDE5A (0.42) PDE5A
SCHEMBL30961016 0.91 HTR6 (0.37) HTR6PDE5AMAPK9MAPK10ADORA2A
SCHEMBL23576879 0.91 HTR6 (0.37) HTR6PDE5AMAPK9MAPK10ADORA2A
SCHEMBL23601533 0.89 SMN1; SMN2 (0.40) PDE5A
SCHEMBL30961006 0.88 HTR1D (0.44) PDE5A
SCHEMBL23577122 0.88 HTR1D (0.44) PDE5A
SCHEMBL29909324 0.86 HTR1D (0.41) PDE5A
SCHEMBL23576923 0.86 HTR1D (0.41) PDE5A
SCHEMBL23576620 0.86 ABCG2 (0.38) PDE5AMAPK9MAPK10ADORA2A
SCHEMBL29909534 0.86 ABCG2 (0.38) PDE5AMAPK9MAPK10ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 US disclosed
EP-4081305-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2022-11-02 EP disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTR6 3342/4885PDE5A 1924/4885MAPK9 240/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTR6 3342/4885PDE5A 1924/4885MAPK9 240/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK HTR6 3342/4885PDE5A 1924/4885MAPK9 240/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK HTR6 3342/4885PDE5A 1924/4885MAPK9 240/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTR6 3342/4885PDE5A 1924/4885MAPK9 240/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTR6 3342/4885PDE5A 1924/4885MAPK9 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.